natgillin/translations-raw huggingface dataset:
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound bixafen. 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži spoj formule (I) [image] pri čemu je R1 difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; te
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbomene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A sustained release pharmaceutical dosage form comprising 40 mg of oxycodone or a pharmaceutically acceptable salt thereof and 20 mg of naloxone or a pharmaceutically acceptable salt thereof with oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof being present in a ratio of 2:1 by weight for use in the treatment of moderate to severe pain and opioid bowel dysfunction syndromes occurring during pain therapy, wherein said opioid bowel dysfunction syndrome is constipation, and adverse events, wherein said adverse events are elicited naloxone typical adverse events selected from the group consisting of abdominal pain, cramping and diarrhea. 
Farmaceutski oblik doziranja s produljenim oslobađanjem koji sadrži 40 mg oksikodona ili njegove farmaceutski prihvatljive soli i 20 mg naloksona ili njegove farmaceutski prihvatljive soli, gdje su oksikodon ili njegova farmaceutski prihvatljiva sol i nalokson ili njegova farmaceutski prihvatljiva sol prisutni u težinskom omjeru od 2:1, za upotrebu u liječenju umjerene do jake boli i opioidom izazvanih sindroma crijevne disfunkcije koji se javljaju tijekom terapije protiv bolova, gdje je navedeni opioidom izazvani sindrom crijevne disfunkcije zatvor, i neželjenih efekata, gdje su navedeni neželjeni efekti tipični naloksonom izazvani neželjeni efekti odabrani iz skupine koja se sastoji od bolova u trbuhu, grčeva i dijareje.
A pharmaceutical dosage form according to claim 1 for use in the treatment of moderate to severe pain and opioid bowel dysfunction syndromes occurring during pain therapy, wherein said opioid bowel dysfunction syndrome is constipation, and adverse events, wherein said adverse events are elicited naloxone typical adverse events selected from the group consisting of abdominal pain, cramping and diarrhea, wherein said pharmaceutically acceptable salt is the hydrochloride, sulphate, bisulphate, tartrate, nitrate, citrate, bitatrate, phosphate, malate, maleate, hydrobromide, hydroiodide, fumarate or succinate. 
Farmaceutski oblik doziranja prema patentnom zahtjevu 1 za upotrebu u liječenju umjerene do jake boli i opioidom izazvanih sindroma crijevne disfunkcije koji se javljaju tijekom terapije protiv bolova, gdje je navedeni opioidom izazvani sindrom crijevne disfunkcije zatvor, i neželjenih efekata, gdje su navedeni neželjeni efekti tipični naloksonom izazvani neželjeni efekti odabrani iz skupine koja se sastoji od bolova u trbuhu, grčeva i dijareje, gdje je navedena farmaceutski prihvatljiva sol hidroklorid, sulfat, bisulfat, tartrat, nitrat, citrat, bitatrat, fosfat, malat, maleat, hidrobromid, hidroiodid, fumarat ili sucinat.
A pharmaceutical dosage form according to claim 1 or 2 for use in the treatment of moderate to severe pain and opioid bowel dysfunction syndromes occurring during pain therapy, wherein said opioid bowel dysfunction syndrome is constipation, and adverse events, wherein said adverse events are elicited naloxone typical adverse events selected from the group consisting of abdominal pain, cramping and diarrhea, wherein the dosage form has been formulated for oral application. 
Farmaceutski oblik doziranja prema patentnom zahtjevu 1 ili 2 za upotrebu u liječenju umjerene do jake boli i opioidom izazvanih sindroma crijevne disfunkcije koji se javljaju tijekom terapije protiv bolova, gdje je navedeni opioidom izazvani sindrom crijevne disfunkcije zatvor, i neželjenih efekata, gdje su navedeni neželjeni efekti tipični naloksonom izazvani neželjeni efekti odabrani iz skupine koja se sastoji od bolova u trbuhu, grčeva i dijareje, gdje je oblik doziranja formuliran za oralnu primjenu.
represents hydrogen or C1-4 alkyl group; 
predstavlja vodik ili C1-4 alkil skupinu;
A compound of claim 1, wherein Q represents C1-4 alkyl, NR3R4 or 4-morpholinyl group, R1 represents hydrogen atom or C1-4 alkyl group; 
Spoj prema zahtjevu 1, naznačen time, da Q predstavlja C1-4 alkil, –NR3R4 ili 4-morfolinil skupinu,
and, where appropriate, separating the enantiomers and/or diiastereomers, and/or cis- and/or trans- isomers of compounds of formula (I), or intermediates thereto, by conventional methods, and optionally thereafter forming salts and/or hydrates and/or solvates of the compound of formula (I). 
i, gdje je prikladno, odvajanje enantiomera i/ili dijastereomera, i/ili cis- i/ili trans-izomera spojeva formule (I), ili njihovih intermedijera, konvencionalnim postupcima, te nakon toga, opcijski, oblikovanje soli i/ili hidrata i/ili solvata spoja formule (I).
The use of a compound of formula (I) according to claim 1 in the manufacture of a medicament for the treatment and/or prevention of psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders, psychotic depression, mania, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, depression and depressive states, anxiety disorders, sexual dysfunctions, sleep disorders, emesis, aggression, autism or pain. 
Uporaba spoja formule (I) prema zahtjevu 1, naznačena time, da je za proizvodnju lijeka za liječenje i/ili prevenciju psihoza, zlouporabe droge, kognitivnog pogoršanja popratnih pojava shizofrenije, blagog do umjerenog kognitivnog deficita, demencije, psihotičnih stanja povezanih s demencijom, poremećaja hranjenja, poremećaja kod pomanjkanja pažnje, poremećaja hiperaktivnosti, psihotične depresije, manije, bipolarnog poremećaja, paranoidnih i deluzijskih poremećaja, diskinetičkih poremećaja, depresije i deprisivnih stanja, poremećaja anksioznosti, seksualnih disfunkcija, poremećaja spavanja, emezije, agresije, autizma ili bolova.
The use according to claim 9, wherein the psychosis is schizophrenia or a schizo-affective disorder; the drug abuse is alcohol, cocaine, nicotine or opioid abuse; the eating disorder is bulimia nervosa; the dyskinetic disorder is Parkinson's disease, neuroleptic induced parkinsonism or tardive dyskinesia; the sexual dysfunctions is erectile dysfunctions. 
Uporaba prema zahtjevu 9, naznačena time, da psihoza je shizofrenija ili shizo-afektivan poremećaj; zlouporaba droga je zlouporaba alkohola, kokaina, nikotina ili opijata; poremećaj hranjenja je neurozna bulimija; diskinetički poremećaj je Parkinson-ova bolest, neuroleptički proizveden parkinsonizam ili tardivna diskinezija; seksualna disfunkcija je erektivna disfunkcija.
A compound of formula (I) according to claim 1 for use in treating and/or preventing psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders, psychotic depression, mania, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, depression and depressive states, anxiety disorders, sexual dysfunctions, sleep disorders, emesis, aggression, autism or pain. 
Spoj formule (I) prema zahtjevu 1, naznačen time, da se koristi za liječenje i/ili prevenciju psihoza, zlouporabe droge, kognitivnog pogoršanja popratnih pojava shizofrenije, blagog do umjerenog kognitivnog deficita, demencije, psihotičnih stanja povezanih s demencijom, poremećaja hranjenja, poremećaja kod pomanjkanja pažnje, poremećaja hiperaktivnosti, psihotične depresije, manije, bipolarnog poremećaja, paranoidnih i deluzijskih poremećaja, diskinetičkih poremećaja, depresije i deprisivnih stanja, poremećaja anksioznosti, seksualnih disfunkcija, poremećaja spavanja, emezije, agresije, autizma ili bolova.
The compound of claim 11, wherein the psychosis is schizophrenia or a schizo-affective disorder; the drug abuse is alcohol, cocaine, nicotine or opioid abuse; the eating disorder is bulimia nervosa; the dyskinetic disorder is Parkinson's disease, neuroleptic induced parkinsonism or tardive dyskinesia; the sexual dysfunctions is erectile dysfunctions. 
Spoj prema zahtjevu 11, naznačen time, da psihoza je shizofrenija ili shizo-afektivan poremećaj; zlouporaba droga je zlouporaba alkohola, kokaina, nikotina ili opijata; poremećaj hranjenja je neurozna bulimija; diskinetički poremećaj je Parkinson-ova bolest, neuroleptički proizveden parkinsonizam ili tardivna diskinezija; seksualna disfunkcija je erektivna disfunkcija.
freezing the freshly harvested AFA alga and thawing it, or, if the starting material is dried AFA powder, sonicating the water-diluted AFA powder to disrupt the cells; 
zamrzavanje svježe sakupljene alge AFA i odmrzavanje ili ako je početni materijal sušeni AFA prašak, sonificiranje u vodi otopljenog AFA praška da se razbiju stanice,
centrifuging the product of step a) to separate the supernatant from the precipitate; 
centrifugiranje produkta iz koraka a) da se odvoji supernatant od taloga,
collecting the supernatant containing the water-soluble components, for the manufacture of a composition for preventing, controlling or treating one of the following neurological disease, condition, dysfunction or disorder: Alzheimer disease, Parkinson diseases, multiple sclerosis, hyperactivity and attention deficit disorders (ADHD), autism, depression, memory deficit and mood disturbances. 
sakupljenje supernatanta koji sadrži u vodi topljive komponente za preparaciju pripravka za prevenciju, kontrolu i tretman sljedećih neuroloških bolesti, stanja, disfunkcija i poremećaja: Alzheimerova bolest, Parkinsonova bolest, multipla skleroza, hiperaktivnost i poremećaj nedostatka pažnje (ADHD), autizam, depresija, nedostatak memorije i poremećaji raspoloženja.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A high-strength pearlitic steel rail with an excellent combination of wear properties and rolling contact fatigue resistance wherein the steel consists of 0.88% to 0.95% carbon, 0.75% to 0.95% silicon, 0.80% to 0.95% manganese, 0.05% to 0.14% vanadium, up to 0.008% nitrogen, up to 0.030% phosphorus, 0.008 to 0.030% sulphur, at most 2.5 ppm hydrogen, at most 0.10% chromium, at most 0.010% aluminium, at most 20 ppm oxygen, the remainder being iron and unavoidable impurities. 
Tračnica od perlitnog čelika visoke čvrstoće s odličnom kombinacijom svojstava trošenja i otpornosti na zamor pri kotrljajućem kontaktu, naznačena time da se čelik sastoji od 0.88 do 0.95% ugljika, od 0.75 do 0.95% mangana, od 0.05 do 14% vanadija, do 0.008% dušika, do 0.030% fosfora, od 0.008 do 0,30% sumpora, najviše 2.5 ppm vodika, najviše 0.010% aluminija, najviše 20 ppm kisika i ostatka koji čine željezo i neizbježna onečišćenja.
Pearlitic rail according to any one of the preceding claims having an RCF resistance of at least 130,000 cycles to initiation under water lubricated twin disc testing conditions. 
Perlitna tračnica prema bilo kojem prethodno navedenom patentnom zahtjevu, naznačena time da je otpornost na zamor pri kotrljajućem kontaktu barem 130.000 ciklusa do početka, u uvjetima ispitivanja metodom dvostrukog diska umočenog u vodu.
A stabilizer for a freeze-dried live attenuated canine distemper (CDV and canine parainfluenza type 2 (cPi2) immunogenic composition comprising at least one reducing monosaccharide and at least one acid antioxidant compound, wherein the at least one acid antioxidant compound comprises aspartic acid; and wherein the at least one reducing monosaccharide comprises glucose, galactose, fructose, mannose, sorbose, or combinations thereof; and wherein the at least one reducing monosaccharide is at a concentration from about 20% to about 50% w/w and the at least one acid antioxidant is at a concentration from about 1.5% to about 6% w/w. 
Stabilizator za zamrzavanjem osušenu živu atenuiranu imunogenu smjesu virusa štenećaka pasa (CDV) i virusa parainfluence pasa tipa 2 (cPi2) koja sadrži najmanje jedan redukcijski monosaharid i najmanje jedan spoj kiselog antioksidansa, pri čemu taj najmanje jedan spoj kiselog antioksidansa sadrži asparaginsku kiselinu; i pri čemu najmanje jedan redukcijski monosaharid sadrži glukozu, galaktozu, fruktozu, manozu, sorbozu ili njihove kombinacije; i pri čemu je najmanje jedan redukcijski monosaharid u koncentraciji od oko 20% do oko 50% tež./tež. i najmanje jedan kiseli antioksidans je u koncentraciji od oko 1.5% do oko 6% tež./tež.
at least one bulking agent wherein the at least one bulking agent comprises dextran, maltodextrin, polyvinylpyrrolidone, hydroxyethyl starch, or combinations thereof or 
najmanje jedno punilo pri čemu to najmanje jedno punilo sadrži dekstran, maltodekstrin, polivinilpirolidon, hidroksietil škrob ili njihove kombinacije ili
The immunogenic suspension or solution of claim 3, wherein the immunogenic suspension or solution is a multivalent immunogenic suspension or solution that further comprises at least one active immunogenic component derived from a pathogen other than paramyxovirus. 
Imunogena suspenzija ili otopina prema patentnom zahtjevu 3, gdje je imunogena suspenzija ili otopina multivalentna immunogena suspenzija ili otopina koja dalje sadrži najmanje jednu aktivnu imunogenu komponentu porijeklom od patogena koji se razlikuje od paramiksovirusa.
the at least one active immunogenic component is derived from a pathogen comprising Adenoviridae, Parvoviridae, Coronaviridae, Herpesviridae, Poxvirididae, Rhabdoviridae, or combinations thereof or 
najmanje jedna aktivna imunogena komponenta porijeklom je od patogena koji sadrži Adenoviridae, Parvoviridae, Coronaviridae, Herpesviridae, Poxvirididae, Rhabdoviridae ili njihove kombinacije ili
at least one sugar alcohol at a final concentration from about 0.5% to about 5% w/v, at least one non-reducing oligosaccharide at a final concentration from about 0.5% to about 5% w/v, and at least one reducing monosaccharide, with the proviso that the final concentration of reducing monosaccharide, sugar alcohol and non-reducing oligosaccharide is equal to or less than about 12.5% w/v. 
najmanje jedan šećerni alkohol u konačnoj koncentraciji od oko 0.5% do oko 5% tež./vol., najmanje jedan ne-redukcijski oligosaharid u konačnoj koncentraciji od oko 0.5% do oko 5% tež./vol., i najmanje jedan redukcijski monosaharid, uz uvjet da je konačna koncentracija redukcijskog monosaharida, šećernog alkohola i ne-redukcijskog oligosaharida jednaka ili manja od oko 12.5% tež./vol.
a final concentration from about 1% to about 5% w/v of at least one reducing monosaccharide, (ii) a final concentration from about 0.5% to about 5% w/v of at least one sugar alcohol, (iii) a final concentration from about 0.1 % to about 0.3% w/v of at least one acid antioxidant, with the proviso that the final concentration of (i) and (ii) is equal to or less than about 7.5% w/v or 
konačnu koncentraciju od oko 1% do oko 5% tež./vol. najmanje jednog redukcijskog monosaharida, (ii) konačnu koncentraciju od oko 0.5% do oko 5% tež./vol. najmanje jednog šećernog alkohola, (iii) konačnu koncentraciju od oko 0.1 % do oko 0.3% tež./vol. najmanje jednog kiselog antioksidansa, uz uvjet da je konačna koncentracija (i) i (ii) jednaka ili manja od oko 7.5% tež./vol. ili
a final concentration from about 1.5% to about 4% w/v of at least one reducing monosaccharide, (ii) a final concentration from about 1.5% to about 3% w/v of at least one sugar alcohol, and (iii) a final concentration from about 0.1% to about 0.25% w/v of at least one acid antioxidant, with the proviso that the final concentration of (i) and (ii) is equal to or less than about 5% w/v or 
konačnu koncentraciju od oko 1.5% do oko 4% tež./vol. najmanje jednog redukcijskog monosaharida, (ii) konačnu koncentraciju od oko 1.5% do oko 3% tež./vol. najmanje jednog šećernog alkohola, i (iii) konačnu koncentraciju od oko 0.1% do oko 0.25% tež./vol. najmanje jednog kiselog antioksidansa, uz uvjet da je konačna koncentracija (i) i (ii) jednaka ili manja od oko 5% tež./vol. ili
The immunogenic composition of claim 8, further comprising at least one active immunogenic component derived from a pathogen other than paramyxovirus. 
Imunogena smjesa prema patentnom zahtjevu 8, koja dalje sadrži najmanje jednu aktivnu imunogenu komponentu porijeklom od patogena osim paramiksovirusa.
The immunogenic composition of claim 10, wherein the at least one active immunogenic component 
Imunogena smjesa prema patentnom zahtjevu 10, gdje je najmanje jedna aktivna imunogena komponenta
is derived from a pathogen comprising Adenoviridae, Parvoviridae, Coronaviridae, Herpesviridae, Poxviridae, Rhabdoviridae, or combinations thereof or 
porijeklom od patogena koji sadrži Adenoviridae, Parvoviridae, Coronaviridae, Herpesviridae, Poxviridae, Rhabdoviridae ili njihove kombinacije ili
The multivalent immunogenic composition of claim 12, wherein the at least one active immunogenic component 
Multivalentna imunogena smjesa prema patentnom zahtjevu 12, gdje je najmanje jedna aktivna imunogena komponenta
A process for freeze-drying a live attenuated CDV and cPi2 immunogenic suspension or solution, which comprises (a) contacting the live attenuated CDV and cPi2 immunogenic suspension or solution with a stabilizer as defined in claim 1 or 2, thereby forming a stabilized immunogenic suspension or solution; (b) cooling, at atmospheric pressure, the stabilized immunogenic suspension or solution to a temperature of less than about the Tg value of the stabilized immunogenic suspension; (c) drying the stabilized immunogenic suspension or solution by sublimation of ice at low pressure; and (d) removing excess residual water by further reducing pressure and increasing the temperature of the stabilized immunogenic suspension or solution. 
Postupak za sušenje zamrzavanjem imunogene suspenzije ili otopine živog atenuiranog CDV i cPi2, a obuhvaća (a) dovođenje u kontakt suspenzije ili otopine živog atenuiranog CDV i cPi2 sa stabilizatorom prema patentnom zahtjevu 1 ili 2, čime se formira stabilizirana imunogena suspenzija ili otopina; (b) hlađenje, na atmosferskom tlaku, stabilizirane imunogene suspenzije ili otopine do temperature manje od oko Tg vrijednosti stabilizirane imunogene suspenzije; (c) sušenje stabilizirane imunogene suspenzije ili otopine sublimacijom leda na niskom tlaku; i (d) uklanjanje viška preostale vode dodatnim snižavanjem tlaka i povećavanjem temperature stabilizirane imunogene suspenzije ili otopine.
A compound according to Claim 1 selected from the group consisting of compounds of Formula I and IA wherein: 
Spoj prema zahtjevu 1izabran iz grupe koja obuhvaća spojeve Formule I i IA gdje:
is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the heteroaryl; is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more R6's; 
je vodik, alkil, alkoksi, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil ili heterociklilalkil, gdje heteroaril; je alkil, alkenil, aril, cikloalkil, heteroaril ili heterociklil, od kojih svaki može biti po izboru supstituiran jednim ili više R6;
is heteroaryl or -C(=O)OR5, wherein the heteroaryl may be optionally substituted with one or more R6's; is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl; is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more R6's; 
je heteroaril ili -C(=O)OR5, gdje heteroaril može biti po izboru supstituiran jednim ili više R6; je vodik, alkil, alkoksi, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil ili heterociklilalkil; je alkil, alkenil, aril, cikloalkil, heteroaril ili heterociklil, od kojih svaki može biti po izboru supstituiran jednim ili više R6;